Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday.

A number of other research analysts also recently commented on SUPN. Jefferies Group LLC set a $35.00 price objective on Supernus Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, May 10th. Cowen and Company upped their price objective on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, May 11th. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, May 11th. Piper Jaffray Companies upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $30.00 to $44.00 in a research note on Thursday, June 1st. Finally, Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Thursday, July 13th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $48.43.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) opened at 45.65 on Thursday. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $46.45. The company has a 50-day moving average of $42.54 and a 200 day moving average of $34.58. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of 23.03 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The business had revenue of $75.83 million during the quarter, compared to the consensus estimate of $68.54 million. On average, equities analysts forecast that Supernus Pharmaceuticals will post $1.04 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/17/supernus-pharmaceuticals-inc-supn-lifted-to-buy-at-bidaskclub.html.

In related news, VP Padmanabh P. Bhatt sold 2,500 shares of the company’s stock in a transaction on Friday, May 26th. The stock was sold at an average price of $35.90, for a total transaction of $89,750.00. Following the completion of the transaction, the vice president now directly owns 37,500 shares in the company, valued at approximately $1,346,250. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $45.23, for a total value of $167,758.07. Following the transaction, the vice president now owns 17,500 shares of the company’s stock, valued at $791,525. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 28,000 shares of company stock valued at $1,130,524. 6.70% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. boosted its position in Supernus Pharmaceuticals by 3,455.2% in the second quarter. Meeder Asset Management Inc. now owns 2,382 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 2,315 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in Supernus Pharmaceuticals during the first quarter valued at about $127,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Supernus Pharmaceuticals by 278.2% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC boosted its position in Supernus Pharmaceuticals by 91.4% in the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 1,462 shares during the last quarter. Finally, Advisor Group Inc. boosted its position in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after buying an additional 410 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.